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Abstract: The use of pharmacogenomics to personalize drug therapy has been a long-sought goal
for warfarin and tamoxifen. However, conflicting evidence has created reason for hesitation in
recommending pharmacogenomics-guided care for both drugs. This review will provide a summary
of the evidence to date on the association between cytochrome P450 enzymes and the clinical end
points of warfarin and tamoxifen therapy. Further, highlighting the clinical experiences that we
have gained over the past ten years of running a personalized medicine program, we will offer our
perspectives on the utility and the limitations of pharmacogenomics-guided care for warfarin and
tamoxifen therapy.
Keywords: pharmacogenomics; warfarin; tamoxifen; cytochrome P450

1. Introduction
Warfarin and tamoxifen are widely prescribed and clinically important drugs for the treatment of
conditions that require anticoagulation and estrogen receptor (ER)-positive breast cancer, respectively.
The clinical response and efficacy of both drugs are variable likely due in part to genetic differences in
pharmacogenes that mediate their metabolism and clearance. While genomics-based clinical guidelines
have been established for several drugs, whether pharmacogenomics can be used to personalize
treatment for individual patients remains controversial for warfarin and tamoxifen. This review
aims to discuss the evidence to date that seek to correlate pharmacogenomic testing and the clinical
outcomes in the context of each drug. Further, we will provide clinical insights and future perspectives
based on our experiences with the implementation of personalized medicine strategies for warfarin
and tamoxifen within a large acute care hospital setting.
2. Personalizing Warfarin Therapy
Warfarin is an oral anticoagulant that is indicated for the treatment and prevention of thrombosis
related complication such as stroke and pulmonary embolism among patients with atrial fibrillation,
prosthetic heart valves and venous thrombosis. Warfarin is an inhibitor of vitamin K epoxide reductase
complex subunit 1 (VKORC1), which prevents the cycling of vitamin K to its active metabolite.
Reduction in levels of active vitamin K1 leads to a deficiency in many components for the coagulation
cascade including factors II, VII, IX, and X. Vitamin K antagonism has proven to be difficult to
manage due to marked interpatient variability of response originating from genetic, environmental and
iatrogenic influences. Warfarin therapy requires frequent monitoring of the international normalized
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ratio (INR) of prothrombin time. Healthy individuals have an INR near 1 and the target range for
the majority of warfarin-treated patients is 2–3. Out of range INR can be a warning sign of reduced
medication compliance, dietary changes, and potential drug interactions that increase the risk of
adverse events, where low INR fails to prevent thrombotic events and high INR results in increased
risk of bleeding [1]. The adverse event rate for warfarin therapy is a major difficulty that is confronted
by clinicians. For example, Budnitz et al. found that adverse drug events accounted for 2.5% of visits
to American emergency departments, and that warfarin alone accounted for approximately 6% of
these visits [2]. A follow up study in elderly adults over 65 years of age demonstrated that 3.6% of
emergency department visits were due to adverse drug reactions, of which 17% were attributable to
warfarin [3]. The dangerously high adverse event rate with warfarin usage has led to a number of
studies, both in vitro and in vivo, examining the pathways and determinants that govern the observed
variation in warfarin dose response, and development of more predictive dosing algorithms, including
those that take into account patient-specific pharmacogenomic information.
2.1. Warfarin Metabolism by Cytochrome P450s
Warfarin is delivered as a racemic mixture whereby the S-enantiomer is a significantly more
potent inhibitor of VKORC1, to the extent that S-warfarin is believed to be the clinically relevant
compound [4]. The enantiomers are metabolized by different cytochrome P450 (CYP) enzymes [5]
with S-warfarin metabolized by CYP2C9 to the inactive S-7-hydroxywarfarin in the liver (Figure 1) [6].
CYP2C9 is known to harbor common genetic variations. Specifically, CYP2C9 variant alleles *2 and
*3, are not only common, but result in an enzyme with impaired activity and decreased warfarin
turnover in vitro [7,8]. CYP2C9*2 and CYP2C9*3 have been shown to have an allele frequency of
12.5% and 8.5% in Caucasian populations [8], and genotyping for these alleles has demonstrated
correlation with reduced dosage requirements and a greater likelihood of over anticoagulation [9–13].
CYP2C9 genotyping has been found to account for approximately 12% of the variation in warfarin dose
requirement in Caucasian populations [12], leaving a large portion of the variability to be explained by
other genetic factors and the environment.
Cytochrome P450 enzymes also play a direct role in the vitamin K cycle, distinct from their
activity in warfarin metabolism. CYP4F2 has been shown to influence warfarin activity through its
function as a vitamin K1 oxidase, resulting in the removal of vitamin K1 from the vitamin K cycle [14].
Warfarin also breaks the vitamin K cycle by impairing VKORC1 and preventing transformation to
active vitamin K metabolite, therefore CYP4F2 activity increases the effect of warfarin anticoagulation
(Figure 1). Caldwell et al. identified a CYP4F2 nonsynonymous single nucleotide polymorphism (SNP)
rs2108622 that results if V433M coding mutation. This polymorphism (rs2108622) was then shown to
be significantly associated with increased warfarin dose requirements in a Caucasian population [15].
CYP4F2 rs2108622 results in reduced CYP4F2 expression and activity effectively increasing the
homeostatic pool of vitamin K1 that must be reduced for effective anticoagulation, potentially
necessitating an increased dose of warfarin [14]. The rs2108622 variant of CYP4F2 has been predicted
to account for between 1% and 2% of warfarin dose variation in Caucasian populations [12,15]. As well,
CYP4F2 genotyping has demonstrated that the difference in warfarin dosing appears to occur during
the induction phase of treatment [16,17]. Combining the two cytochrome P450 enzymes, CYP2C9 and
CYP4F2, and their variants could predict approximately 15% of the variation in warfarin dose response
in Caucasian populations.
VKORC1 is the target enzyme that is inhibited by warfarin and the rate limiting enzyme in the
vitamin K cycle, allowing for warfarin to effectively prevent the production of vitamin K dependent
coagulation factors (Figure 1) [18,19]. Elucidation of the gene VKORC1 as the target for warfarin
response, through the in-depth genetic assessment of patients exhibiting warfarin resistance was a
crucial discovery that led to the identification of common genetic variations that predict warfarin
dose and sensitivity in the general population [20,21]. Indeed, the VKORC1 SNP rs9923231 (*2)
has now been well established as an important determinant of VKORC1 response to warfarin
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failed to find a statistically significant difference in the same primary outcome, time in therapeutic
range [33]. A trial in Italian Caucasians also failed to detect a difference in time in therapeutic INR
range when compared against a clinically guided dosing algorithm [34].
Discrepancies among clinical trials have led to many questions over the value of
pharmacogenetic-guided dosing. The EU-PACT trial can be criticized for the control group lacking any
standardized clinical algorithm for dosing decisions where the typical loading dose regimen may have
resulted in unreasonable levels of over anticoagulation in the control arm. However, at the time of
publication, the authors argue common practice did not utilize clinical algorithms and dosing with a
standardized format was more translatable [32]. Meanwhile, the COAG trial has received criticism
over the stratification of patients by age and indication for warfarin therapy, with implications that the
atrial fibrillation and venous thromboembolism patients may respond differently to the anticoagulation
effect of warfarin [35]. The EU-PACT trial used pharmacogenetic dosing from day 1 of the trial, while
due to the constraints of the study design, in the COAG trial many patients received pharmacogenetics
information after the first dose and some authors believe it is the earliest dosing that benefits from the
input of pharmacogenetics [34,35]. Additionally, the indication for warfarin use has been implicated
as a determinant factor [35] with a greater benefit predicted in atrial fibrillation [31,36]. While the
EU-PACT and COAG trials differed in the proportion of patients for each indication, no significant
effect was observed upon further analysis by the authors [35]. The largest difference between the
EU-PACT and COAG trials is found within the patient population. The EU-PACT trial consisted
of a largely homogenous population of European Caucasians, while the COAG trial was a mixed
population of Caucasians and African Americans. Ethnic differences in the prevalence of CYP2C9 and
VKORC1 genotypes have long been known, but these trials bring this to the center of the debate.
Compounding the difficulty in understanding the clinical value of pharmacogenetics in warfarin
dosing is the recent publication of the Genetics Informatics Trial (GIFT) of warfarin to prevent deep
vein thrombosis post-operatively in patients older than 65 [37]. GIFT is the largest trial to date, with
1650 patients enrolled across six centres, allowing for the use of clinical outcomes as an endpoint. GIFT
found that genotype guided warfarin dosing improved the composite outcome of major bleeding, INR
> 4, venous thromboembolism, or death, when compared to a clinically guided dosing algorithm. The
scale of GIFT allowed for the power to detect rare events and showed a significant improvement of the
primary outcome between the groups. The secondary outcome in GIFT, time in the therapeutic INR
range, show a significant benefit in the genotype guided group. Interestingly, the largest benefit in
the secondary outcome was observed in patients considered the high-risk subgroup, those where the
genotype and clinical algorithms differed by greater than 1 mg/day. Some key differences between this
and previous trials are the inclusion of CYP4F2*3 genotyping and the application of the algorithm for
11 days, twice as long as previous trials [37]. As well, GIFT enrolled patients with a single indication for
warfarin therapy, thereby potentially influencing the statistical significance of the study and limiting
its translation to other indications. The results of GIFT add to the debate for pharmacogenomics in
warfarin dosing, while the real-world application and cost-effectiveness of these programs has yet to
be tested.
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Table 1. Association of pharmacogenomics with warfarin outcomes.
Studies

Design

N

Population

455

98% White
1% Black
1% Asian

Outcomes

P

CYP2C9*2
CYP2C9*3
VKORC1*2

Improved time within therapeutic INR (67.4% vs. 60.3%); reduction
in INR > 4, reduced time to therapeutic INR

<0.001

CYP2C9*2
CYP2C9*3
VKORC1*2
CYP4F2*3

Reduced composite measure of major bleeding, INR > 4, death, and
VTE (10.8% vs. 14.7%).
In hip and knee arthroplasty patients

<0.02

Alleles

Positive association
Primohamed et al., 2013 [32]

RCT, genotype guided vs. standard dose

Gage et al., 2017 [37]

RCT, genotype guided vs. clinical

1597

91% White
6% Black
2% Asian
1% Other

Caraco et al., 2008 [38]

RCT, Genotype vs. clinical

191

Unavailable

CYP2C9*2
CYP2C9*3

Reduction in time to first therapeutic INR (2.73 days earlier) and
reduction in time to stable INR (18.1 days earlier)

<0.001

CYP2C9*2
CYP2C9*3
VKORC1*2

Pharmacogenomic dose prediction more accurate than clinical dose
prediction (53% vs. 17% of explained variability, respectively)

<0.0001

Gage et al., 2008 [28]

Validation of dosing algorithm

292

93%
Caucasian
15% Black
2% Hispanic

IWPC, 2009 [29]

Validation of dosing algorithm

1009

55% White
30% Asian
10% Black
5% Other

CYP2C9*2
CYP2C9*3
VKORC1*2 #

Pharmacogenomic dose prediction more accurate than clinical dose
prediction (accurately identified 49.4% vs. 33.3% of patients
requiring ≤21 mg warfarin per week, respectively)

<0.001

Gong et al., 2011 [31]

Validation of dosing algorithm

167

95% White
2% Black
2%Asian
1% Other

CYP2C9*2
CYP2C9*3
VKORC1*2
CYP4F2*3

Demonstrated the safe effective prediction of dose limiting variation

N/A

Negative association
Kimmel et al., 2013 [33]

RCT, Genotype guided vs. clinical

1015

66%White
27% Black
7% Hispanic

CYP2C9*2
CYP2C9*3
VKORC1*2

No difference in time in therapeutic INR (45.2% vs. 45.4%)
No difference in anticoagulation control or dose prediction

0.91

Verhoef et al., 2013 [39]

RCT, Genotype guided vs. clinical

1597

98% White

CYP2C9*2
CYP2C9*3
VKORC1*2

No difference in time in therapeutic INR range (61.6% vs. 60.2%)

0.47

Pengo et al., 2015 [34]

RCT, Genotype guided vs. standard

180

100% White

CYP2C9*2
CYP2C9*3
VKORC1*2
CYP4F2*3

No difference in out of range INRs (45.6% vs. 43.6%) or time in
therapeutic INR range (51.9% vs. 53.3%)

0.79
0.71

Anderson et al., 2007 [40]

RCT, Genotype guided vs. standard

200

94% White

CYP2C9*2
CYP2C9*3
VKORC1*2

No difference in time in therapeutic INR range (30.7% vs. 33.1%)

0.47

RCT, randomized control trial; INR, International normalization ratio; VTE, venous thromboembolism; #, VKORC1*2 or one of six other linked SNPs, N/A, not available.
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2.3. Tailoring Pharmacogenomics-Based Warfarin Dosing Algorithms
Pharmacogenomic guided warfarin dosing algorithms continue to show promise to optimize warfarin
dose selection. However, one key caveat that must be kept in mind is that much of the prospective
clinical trials-based evidence has been primarily derived from Caucasian populations. Even among subjects
who reside in similar parts of the world, variant allele frequencies can differ widely. For example, it has
been common knowledge among clinicians that subjects of Asian descent require lower warfarin dosing
on average, and Lee et al. provided evidence that 87% of their Chinese study population harbored the
VKORC1*2 variant. However, within that same study, the Malay cohort carrier frequency was 65% and the
Indian population had much lower rates of 12% [41]. A further review of the prevalence of VKORC1 variants
in east Asian populations found that 90% of study subjects were variant carriers, while in the rest of Asia
there exists a wide range from 14% to 80% in VKORC1 variant carrier frequency [42]. In some studies, such
as the COAG trial, which enrolled a large number of African-American patients, the investigators failed to
include additional SNPs in VKORC1 and CYP2C9 that are more prevalent and more strongly associated with
warfarin dose adjustment in patients of African descent [43]. Indeed, a dosing algorithm using these two
novel markers showed significant improvement on the amount of variation explained (27%) as compared to
the International Warfarin Pharmacogenetics Consortium (IWPC) algorithm (16%), but overall, the power
remains low and further exploration for additional genetic markers in this population is warranted [44].
The variation in allele frequencies between ethnicities impairs the translation of pharmacogenomics-based
warfarin dosing algorithms, as accounting for all of the alleles may be too costly and not accounting for
certain alleles may limit its utility. To effectively implement pharmacogenomics-guided dosing algorithms,
clinicians may need to tailor algorithms for different ethnicities by accounting for alleles that are most
prevalent within that ethnic population.
2.4. Insights from Clinical Implementation of Pharmacogenomics-Guided Warfarin Therapy
Since 2006, our research team has been involved in the implementation of pharmacogenomicsbased personalized medicine for real-world patient care. In 2008, with the support of our hospital
(London Health Sciences Centre, London Ontario Canada), we started a personalized medicine clinic
that was focused on optimization of drug dosing or selection using patient-specific pharmacogenomic
information. Over the past nine years we have obtained informed pharmacogenetics research
consent from over 4000 patients, as part of our personalized medicine research program. We are
able to incorporate clinical assessments, as well as relevant genomics-guided recommendations for
drugs that are known to be affected by pharmacogenetic variation, such as, warfarin, tamoxifen,
azathioprine, tacrolimus, clopidogrel, capecitabine, 5-fluorouracil, and irinotecan. Feedback from
referring physicians indicates that they all value our personalized medicine-based approach to warfarin
dosing. In the following sections, our perspective/opinion, based on our experience of utilizing warfarin
pharmacogenomic information, both for inpatient care and in the ambulatory clinic setting is outlined.
When and how fast to genotype: In our experience, carrying out warfarin pharmacogenomic
testing is valuable during the initiation of warfarin therapy, or when a stable dose of warfarin has not
been attained. Carrying out genotyping for patients who are already at a stable dose and adequate
INR time in therapeutic range is likely unnecessary. The majority of our pharmacogenomics-guided
recommendations are provided within 24 h. However, we noted that for most of the patients who
are just starting warfarin therapy, one or two days of a typical standard dose (e.g., 5 mg) does not
significantly alter INR trajectory even among carriers of risk alleles in VKORC1 or CYP2C9.
Timely discharge from hospital: As our team gained more experience with inpatient consultation
requests for warfarin dosing and management, we learned the capability to predict warfarin dose
based on their pharmacogenomic makeup gives far greater confidence with regards to the dose of
warfarin required at the time of discharge. This is related to the fact that it typically takes 7–10 days,
from initiation of warfarin to reach target INR. Frequently, in a hospitalized setting, the treating
physicians worry about an unexpectedly rapid or slow rise in INR, and tend to keep such patients in
the hospital longer than necessary.

J. Pers. Med. 2017, 7, 20

7 of 20

Warfarin pharmacogenomics can be used as rationale for initiating alternate treatments: The
emergence of direct oral anticoagulants (DOACs) has meant that there is now an alternative to warfarin,
particularly for the patients who require oral anticoagulation for nonvalvular atrial fibrillation or
venous thromboembolism (VTE). For many patients, the cost of DOACs vs. warfarin, may be the key
issue. In our experience, patients who are predicted to require low or very low warfarin dose based
on their pharmacogenomic profile, tend to have more variable INRs and are less able to maintain
adequate time in therapeutic range. Greater bleeding risk among variant carriers in CYP2C9 and
VKORC1 was clearly demonstrated in the Effective Anticoagulation with Factor Xa Next Generation in
Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) clinical trial that
compared edoxaban vs. warfarin [45]. Therefore, for patients in our clinic who are at greater bleeding
risk during the first 90 days of therapy based on their CYP2C9 and VKORCI genetics and who qualify
for either warfarin or DOAC therapy, we are more likely to initiate a DOAC or switch them to a DOAC.
Dedicated expertise and clinic for follow-up still needed: While pharmacogenomic assessment
can provide a reasonable estimate of predicted warfarin dose, routine INR monitoring and further dose
adjustment, regardless of predicted dose, is still required. Moreover, warfarin drug interactions are
common, both from inhibitors of CYP2C9, those that affect gut vitamin K synthesis (e.g., antibiotics),
and inducers of P450 enzymes (e.g., phenytoin, phenobarbital, carbamazepine, rifampin). In severely
ill patients, caution is warranted in terms of over-reliance on pharmacogenomic-based warfarin dose
as such patients tend to be quite ill, often with multi-organ dysfunction and poor oral intake. Therefore,
a team or a clinic with expertise in warfarin dosing and management is highly recommended.
3. Personalizing Tamoxifen Therapy
Tamoxifen, a selective estrogen receptor modulator (SERM) that functions as an antagonist within
the breast and reproductive organs, has been widely used to treat and prevent recurrence of ER-positive
breast cancer since the 1970s [46–48]. While most commonly used as an adjuvant therapy, tamoxifen
was the first drug approved by the US Food and Drug Administration (FDA) as a chemo-preventative
agent for women at high risk for breast cancer. The benefits of long-term endocrine treatment for
improved disease-free survival have been demonstrated in two large randomized controlled trials for
patients with early-stage hormone receptor positive disease, shifting the paradigm of treatment strategy
from 5 years to 10 years of extended tamoxifen therapy [49–51]. Despite a reduction in recurrence
rates, there is high variability observed in response to tamoxifen. Many factors, including disease type,
nodal involvement, drug adherence, concomitant medications, treatment with chemotherapy, and the
presence of pharmacogenetic polymorphisms all likely contribute to variation in tamoxifen efficacy [47].
Currently, the goal of personalized tamoxifen therapy to improve breast cancer outcomes is primarily
focused on understanding the contribution of pharmacogenomics to tamoxifen metabolism [52].
3.1. Tamoxifen Metabolism by Cytochrome P450s
Tamoxifen is a prodrug that undergoes extensive hepatic metabolism by cytochrome P450
enzymes to form primary metabolites 4-hydroxytamoxifen (4-OH-TAM) and N-desmethyl-tamoxifen
(NDM-TAM), which are both further converted to 4-hydroxy-N-desmethyl-tamoxifen, better known
as endoxifen [46]. It is well established that the rate limiting enzyme in tamoxifen to endoxifen
bioactivation is CYP2D6, while other enzymes (CYP3A4, CYP2C9, CYP2C8, and CYP2C19) likely
have a smaller contribution [46,47]. While 4-OH-TAM and endoxifen share similar affinities for ER
binding, approximately 100-fold greater than tamoxifen itself, endoxifen is considered to play the
lead efficacious role [53]. Circulating endoxifen concentration is on average six times greater than
4-OH-TAM, and has been shown in vitro to cause ERα degradation in a concentration dependent
manner [53,54]. Endoxifen concentrations are highly variable among patients, ranging from <5 nM to
>100 nM, with CYP2D6 being thought to be the main source driving this variability [55].
CYP2D6, primarily expressed in the liver, is responsible for the metabolism of approximately 25% of
prescription drugs currently on the market [46]. To date, there are over 100 identified single nucleotide
polymorphisms (SNPs) within CYP2D6, making it the most polymorphic CYP enzyme [56]. In addition,
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patients can carry multiple copies of CYP2D6. The presence of decreased (e.g., *9, *10, *17, *41) or null
(e.g., *3, *4, *5, *6, *7, *8) function variants can be translated to a phenotypic classification of CYP2D6
metabolic activity as either intermediate metabolizer (IM) or poor metabolizer (PM), respectively, while
patients without these variants are normal metabolizers (NM) or ultrarapid metabolizers (UM) if multiple
copies of CYP2D6 are present [46,47]. In an effort to standardize terms for clinical pharmacogenomic
results, the Clinical Pharmacogenetics Implementation Consortium has redefined CYP2D6 extensive
metabolizers (EM) as normal metabolizers, and as such, will be referred to as NMs within this review [57].
It is well established that CYP2D6 metabolic activity correlates with endoxifen concentration with PMs
having significantly lower systemic exposure [58–61]. However, there is marked interpatient variation in
endoxifen concentration that is observed within CYP2D6 phenotype groups. It is likely that some of this
variation can be explained by the lack of standardization for determining CYP2D6 activity. The number
of variants interrogated, their differential effect on CYP2D6 activity, and how they are combined to define
phenotype can create a source of discordance. For example, using simple phenotyping, patients with
*1/*41 and *41/*4 genotypes would both be categorized as IMs, while the effect of each genotype on
CYP2D6 activity is considerably different. To better describe metabolic activity, many studies have used
more defined phenotypic groups (e.g., NM/IM and IM/PM) or have opted to implement a CYP2D6
activity score (AS) in place of phenotype, where the AS is considered the sum of the values assigned to
each CYP2D6 allele (e.g., *1/*41 and *41/*4 would have AS of 1.5 and 0.5, respectively) [62].
The extent of variation in CYP2D6 activity due to the presence of variant alleles differs among
ethnicities [63,64]. The CYP2D6 PM phenotype is more commonly observed in Caucasians due to
the higher prevalence of the non-functional alleles CYP2D6*4 and *5. Gene duplications leading to
genotype defined UMs and the reduced function *41 allele are most prevalent in Middle Eastern
populations [63]. The high frequency (approximately 41%) of the reduced function *10 allele among
Asians suggests that CYP2D6 mediated drug metabolism may be slower in this population [64].
Approximately, 35% of the allele variation observed in African and African American populations is
comprised of reduced function alleles, primarily *17 and *29, respectively, with African Americans
having a higher frequency of non-functional alleles [63,64]. The likelihood of yet unidentified
functionally consequential variants poses a further challenge when comparing results between studies
from patients of different ethnic backgrounds.
In addition to genotype, CYP2D6 activity can be affected by the co-administration of interacting
medications. Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for depression,
but are also frequently used to alleviate hot flash symptoms, one of the most common side effects of
tamoxifen therapy [46,65]. SSRIs, can be classified as mild, moderate, and strong inhibitors based on
their demonstrated ability to inhibit the metabolic activity of CYP2D6. When taken concomitantly with
tamoxifen, strong inhibitors, such as paroxetine, fluoxetine, and buproprion, can result in a dramatic
reduction in the ability to form endoxifen [66] and may impact tamoxifen efficacy [67]. The use of
moderate (duloxetine, sertraline) and mild (venlafaxine, desvenlafaxine, citalopram, and escitalopram)
inhibitors are thought to have less of an impact on tamoxifen metabolism, however, the individual
effect may vary significantly suggesting that if a SSRI is required the lowest dose of a mild inhibitor
should be the preferred option to minimize the impact on CYP2D6 activity [65].
3.2. CYP2D6 and Tamoxifen Clinical Outcomes
The importance of CYP2D6 to tamoxifen metabolism and subsequent endoxifen formation has
provided logical rationale for the hypothesis that CYP2D6 genotype correlates with tamoxifen efficacy.
If CYP2D6 genotype correlated strongly with outcomes, then up-front genotyping tests could be
offered to predict the risk of recurrence. For higher risk patients with reduced or absent CYP2D6
activity, alternate dosing or treatment strategies could be proactively offered to personalize endocrine
therapy potentially improving survival outcomes. However, studies spanning the past two decades
fail to provide conclusive evidence for recommending CYP2D6 genotyping as a predictive marker of
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tamoxifen efficacy. While some studies have demonstrated a significant correlation, many have failed
to reproduce these results (summarized in Table 2).
Early studies observed significant correlation between null and reduced CYP2D6 activity alleles and
worse disease outcomes, including higher rates of recurrence [68–70]. Similarly, Lammers et al. found that
CYP2D6 PM phenotype was associated with shorter overall survival (OS) in metastatic breast cancer patients
prescribed 40 mg daily tamoxifen. This study also showed that CYP2D6 inhibitor use was an independent
predictor of OS [71]. Schroth et al. conducted a large retrospective study with a median follow up period
of 6.3 years, including United States (US) and German cohorts of post-menopausal women diagnosed
with early breast cancer and demonstrated that patients with reduced or non-function CYP2D6 alleles had
worse disease-free survival (DFS) [72]. Further, CYP2D6 PM phenotype was found to be associated with a
higher risk of disease events only in the tamoxifen arm of the Austrian Breast and Colorectal Cancer Study
Group trial (ABCSG) 8. This increased risk was not observed in patients who switched to the aromatase
inhibitor anastrozole after two years of tamoxifen [73]. Disease outcomes were also correlated with CYP2D6
activity when phenotype was categorized based on activity score rather than metabolizer status [74,75].
In addition, several studies have shown that homozygosity for CYP2D6 *10, which is more prevalent in
Asian populations, was associated with worse DFS and recurrence-free survival (RFS) [76,77]. Kiyotani et al.
conducted a study with 282 Japanese breast cancer patients receiving tamoxifen monotherapy, and showed
that the presence of two variant alleles was associated with worse RFS [78]. Recently, Saladores et al. found
that poor CYP2D6 activity correlated with shorter distant relapse free survival, irrespective of ethnicity [75].
CYP2D6 PM male breast cancer patients have also been shown to have a higher risk of recurrence, which
remained significant when adjusted for nodal status and tumor size [79].
Retrospective data from two large double-blind trials, the Arimidex, Tamoxifen, Alone, or in
Combination (ATAC) and the Breast International Group (BIG) 1–98 trial, sparked controversy by failing to
validate an association between CYP2D6 genotype and tamoxifen efficacy [80,81]. A large population based
case-cohort study in the United Kingdom (UK) also failed to observe an association between the common
CYP2D6*4 variant and breast cancer specific survival, however, they did note that the null CYP2D6*6 allele
may affect survival in patients taking tamoxifen [82]. Other studies investigating the role of *4 and reduced
function variants in patients from various ethnicities, including a recent study by Hertz et al., were unable
to validate a predictive role for CYP2D6 [83–86]. Interestingly, Kiyotani et al. noted that although no
association between CYP2D6 genotype and RFS was observed in patients receiving tamoxifen-combination
therapy, a significant association was shown in patients on tamoxifen monotherapy [87]. They suggest that
the difference in tamoxifen regimen could explain some of the contradictions in the literature, as many
studies failing to validate a role for CYP2D6 were comprised of patients on combination therapy.
Study heterogeneity resulting from varying inclusion criteria, length of treatment, concomitant
medications, adherence data, measured outcomes, and DNA sources combined with non-standardized
genotype classification has impeded the ability to conclusively determine the association between CYP2D6
phenotype and tamoxifen efficacy. To address heterogeneity related to use of DNA extracted from tumor
infiltrated tissue, Ahern et al. conduced a quantitative bias analysis based on observed concordance rates of
CYP2D6 genotypes to examine whether call errors could bias the estimates of association. They determined
that genotyping errors have a negligible effect on measured outcomes, suggesting that DNA source
is unlikely to be a major contributor to study discrepancies [85]. Recently, several meta-analyses have
been conducted to ascertain the benefit of CYP2D6 genotyping [88–92]. Results from the International
Tamoxifen Pharmacogenomics Consortium meta-analysis from studies conducted globally, suggested that
CYP2D6 might indeed impact tamoxifen benefit [91]. While most of the analyses conducted to date have
demonstrated that CYP2D6 variant phenotypes appear to be associated with reduced survival outcomes,
the associations are based upon small, heterogeneous studies with large differences in comparator groups.
As such, CYP2D6 is likely important for tamoxifen efficacy, but there remains insufficient robust evidence
to support the recommendation of CYP2D6 genotyping for personalizing tamoxifen therapy. As most
studies to date have been retrospective in nature, large, well-designed prospective studies with more
homogenous populations are required to fully elucidate the predictive value of CYP2D6.

J. Pers. Med. 2017, 7, 20

10 of 20

Table 2. Association of CYP2D6 pharmacogenomics with tamoxifen outcomes.
Studies

N

Alleles

DNA Source

Conclusions

Outcome

HR (95% CI)

P

Positive association
Goetz et al., 2005 [68]

190

*4

PE-tissue, buccal swabs

*4/*4 patients had worse RFS and DFS

RFS
DFS

2.71 (1.15–6.41)
2.44 (1.22–4.90)

0.023
0.012

Schroth et al., 2007 [69]

206

*4, *5, *10, *41, CNV

normal breast tissue

Decreased function alleles (*4, *5, *10 and *41) were associated
with higher rates of recurrence and shorter relapse free periods

RFS
EFS

2.24 (1.16–4.33)
1.89 (1.10–3.25)

0.02
0.02

Ramón et al., 2010 [70]

91

33 alleles

blood

Patients with *4/*4, *4/*41, *1/*5 or *2/*5 genotypes had
shorter DFS

Lammers et al., 2010 [71]

99

*3, *4, *5, *6, *10, *41

blood

PMs had worse overall survival compared to NMs

OS

2.09 (1.06–4.12)

0.034

Decreased activity (NM/IM; PM) had worse EFS and DFS

EFS
DFS

1.35 (1.08–1.68)
1.31 (1.06–1.61)

0.007
0.02

0.016

Schroth et al., 2009 [72]

1325

*3,*4, *5, *10, *41

blood, fresh frozen or
PE-tissue

Goetz et al., 2013 [73]

453

*3, *4, *6, *10, *41

PE- tissue

PM/PM patients had higher risk of disease event compared to
NM/NM patients

OR

2.45 (1.05–5.73

0.04

Damodaran et al., 2012 [74]

132

*1, *2, *4, *5, *10

blood

CYP2D6 activity scores <0.5 had worse RFS compared to
activity scores >1

RFS

7.29 (2.92–18.2)

<0.001

Saladores et al., 2015 [75]

587

*3, *4, *5, *6, *9, *10, *41, CNV

blood

Improved DRFS was associated with increased CYP2D6
activity score

DRFS

0.62 (0.43–0.9)

0.013

Xu et al., 2008 [76]

152

*10

blood, fresh frozen or
PE-tissue

*10/*10 was associated with worse DFS

DFS

4.7 (1.1–20.0)

0.04

Kiyotani et al., 2008 [77]

67

*4, *5, *6, *10, *14, *18, *21, *41

blood

*10/*10 genotype had worse RFS

RFS

10.04 (1.17–86.3)

0.036

Kiyotani et al., 2010 [78]

282

*4, *5, *6, *10, *14B, *18, *21, *36,
*41, CNV

blood

Presence of two variant alleles was associated with worse RFS
compared to patients with no variants

RFS

9.52 (2.79–32.45)

<0.0001

Rae et al., 2012 [80]

588

*2, *3, *4, *6, *10, *41

PE-tissue

PMs did not have reduced recurrence rates compared to NMs

RFS

0.99 (0.48–2.08)

0.99

BCFI

0.86 (0.6–1.24)

0.35

Negative association

Regan et al., 2012 [81]

973

*2, *3, *4, *5, *6, *7, *10, *17, *41

PE-tissue

IMs and PMs treated with tamoxifen monotherapy were not
associated with BCFI

Abraham et al., 2010 [82]

3155

*4, *5, *6, *9, *10, *41, CNV

blood

PM/IM patients did not have reduced survival outcomes
compared to NMs

BCSS

0.93 (0.55–1.57)

0.78

Nowell et al., 2005 [83]

160

*3, *4, *6

PE-tissue

*4/*4, *1/*4 were not associated with reduced DFS compared
to *1/*1

DFS

0.67 (0.33–1.35)

0.19

Park et al., 2012 [84]

716

*2, *5, *10, *41

blood

Homozygous variant carriers did not have reduced RFS

RFS

1.14 (0.68–1.92)

0.61

Hertz et al., 2017 [86]

476

*2, *3, *4, *6, *10, *41, CNV

Fresh frozen tumors

CYP2D6 activity score was not associated with RFS

RFS

1.16 (0.84–1.62)

0.37

Kiyotani et al., 2010 [87]

167

*1, *4, *5, *10, *21, *36, *41

blood

No association between genotype and RFS in patients on
tamoxifen-combined therapy

RFS

0.64 (0.20–1.99)

0.44

HR, Hazard ratio; CI, confidence interval; PE, paraffin-embedded; RFS, recurrence free survival; DFS, disease free survival; CNV, copy number variation; EFS, event free survival; NM,
CYP2D6 normal metabolizer; OS, overall survival; IM, CYP2D6 intermediate metabolizer; PM, CYP2D6 poor metabolizer; DRFS, distant relapse free survival; BCFI, breast cancer-free
interval; BCSS, breast cancer specific survival.
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3.3. Tamoxifen Metabolism by Other CYP P450 Enzymes
Tamoxifen metabolism is affected by additional CYP enzymes, including CYP3A4, CYP2C9,
and CYP2C19, however, the overall impact of polymorphisms within these genes appears minor
when compared to CYP2D6 [93–95]. CYP3A4 activity displays high inter-individual variability
and is susceptible to drug interactions [96]. Concomitant administration of rifampicin, a CYP3A4
inducer, surprisingly resulted in the dramatic reduction in plasma endoxifen concentration [97,98].
Additionally, carriers of CYP3A4*22, thought to be a reduced function variant, have been shown
to have significantly increased tamoxifen and metabolite exposure. This effect is more pronounced
in CYP2D6 PMs suggesting that it may provide some functional compensation in the absence of
CYP2D6 metabolic activity [60,99]. Although several studies have failed to find an association between
CYP2C9 variants and tamoxifen metabolism [60,93,100], two studies have observed a significant
effect of CYP2C9 activity on endoxifen concentration [61,95]. The magnitude of this effect was
small and likely does not have significant impact on clinical outcomes [95]. A putative role for
CYP2C19 has been controversial with some studies demonstrating higher endoxifen concentration
and improved outcomes in CYP2C19*17 (increased activity variant) carriers [69,94,101,102], while
other studies failed to validate these findings [100,103]. A recent retrospective analysis of the
International Tamoxifen Pharmacogenomics Consortium dataset of over 2000 patients observed no
effect of CYP2C19 variants (*2, reduced function and *17) on tamoxifen outcomes, an effect that
remained after accounting for CYP2D6 genotype, concluding that CYP2C19 genotype should likely
not be considered when personalizing tamoxifen therapy [104]. The role of phase II enzymes (SULTs
and UGTs) and transporters (ABCB1, ABCC2) have been also been investigated and are reviewed
in [93,105].
SULTs and UGTs play a key role in the metabolism of tamoxifen by catalyzing the inactivation
and subsequent elimination of tamoxifen and its metabolites. Similar to CYP2D6, the genes that
encode for SULTs and UGTs are polymorphic with some variants impacting tamoxifen metabolism.
SULT1A1 is thought to be the primary SULT enzyme that is responsible for the sulfation of
endoxifen and 4-OH-TAM [105]. SULT1A1*2 is associated with reduced activity, but does not
appear to correlate with endoxifen concentrations. However, carriers of SULT1A2 variants, including
SULT1A2*2 and SULT1A2*3 have been associated with higher plasma endoxifen and 4-OH-TAM
concentrations [93,106]. Variants within UGT1A4, UGT2B15, and UGT2B7 have been shown to affect
glucuronidation activity [93]. A study by Romero-Lorca et al. investigated the effect of variants on
the concentration of endoxifen and 4-OH-TAM glucuronidated metabolites. Patients with variants
UGT1A448Val , UGT2B7268Tyr , or with wildtype genotypes for UGT2B17nodel and UGT2B15523Lys exhibited
increased concentrations of active endoxifen and 4-OH-TAM [107]. A recent follow up study by the
same group observed a trend for CYP2D6 PM patients to have higher active metabolite concentrations
if they were carriers of the favorable genotypes they had previously identified, suggesting that
genetic variation in SULTs and UGTs may contribute to improved algorithms for predicting tamoxifen
outcomes [108]. Moreover, a trend for a higher risk of recurrence was noted for patients carrying
a combination of SULT1A1*2/*2:UGT2B15*1/*2 or SULT1A1*2/*2:UGT2B15*2/*2 variant alleles [83].
At present, more studies are needed to better understand the role of SULT and UGT polymorphisms
on tamoxifen metabolism and efficacy.
3.4. Therapeutic Drug Monitoring of Tamoxifen
Amid conflicting results regarding CYP2D6 activity as a biomarker for tamoxifen efficacy,
more studies are now investigating the potential for endoxifen concentration to predict outcomes.
As discussed above, many factors can influence the systemic exposure of endoxifen, therefore,
determining the CYP2D6 genotype is likely not enough to predict the concentration of active metabolite.
Fox et al., reported that greater than 50% of low endoxifen could not be explained by CYP2D6
genotype or use of inhibitory medications [109]. Studies in vitro, as well as in a murine tumor
growth inhibition (TGI) model, have demonstrated that the effect of endoxifen ER antagonism is
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concentration-dependent [61,110]. Based on pharmacokinetic-pharmacodynamic modeling, optimal
TGI was predicted for patients attaining endoxifen concentrations >40 nM, while <15 nM endoxifen
was predicted to achieve sub-optimal (83%) TGI [110]. A putative threshold level of endoxifen has been
demonstrated by two large retrospective studies. Madlensky et al., observed that patients within the
lowest quintile of endoxifen concentration (<15 nM) had higher rates of recurrence when compared to
the upper four quintiles [55]. Similarly, Saladores et al., reported that patients with <14 nM endoxifen
had significantly short distant relapse-free survival as compared to patients with levels >35 nM [75].
Several dose escalation studies have been designed to elevate endoxifen in CYP2D6 PMs and have
consistently shown that an increased daily tamoxifen dose of 30–40 mg can significantly increase levels
to be similar to NM averages, without any noted increase in adverse events [111–115]. Additionally,
Fox et al., performed dose escalations in patients based on baseline endoxifen concentration rather than
CYP2D6 genotype. Patients with <30 nM endoxifen after eight weeks of tamoxifen on the standard
dose (20 mg/day) underwent dose increases by 10 mg/day increments until target endoxifen (>30 nM)
or a maximum of 60 mg/day was reached. Endoxifen levels of >15 nM were achieved in 96% of the
patient cohort after dose escalation when compared to 76% at baseline, with 76% of patients attaining
>30 nM endoxifen [109]. This study demonstrates the potential utility of personalizing tamoxifen
therapy to improve outcomes through therapeutic drug monitoring (TDM) of endoxifen. Patients
with sub-therapeutic endoxifen exposure or poor adherence can be quickly identified within the
first 4–8 weeks after tamoxifen initiation, providing early rationale for clinicians to continue with
tamoxifen therapy or switch to an alternate treatment plan. The use of TDM may be limited in some
clinical settings, therefore the development of algorithms to predict endoxifen concentration based
on clinical, environmental and genetic factors are warranted. An early algorithm developed by our
team based on a patient cohort of approximately 200 patients, achieved a predictive accuracy of 89%,
with a cross validation estimated accuracy of 85% [60]. Larger prospective trials are needed to further
develop highly predictive models and confirm the utility of TDM for personalizing tamoxifen therapy.
The undertaking of such lengthy prospective trials may in fact be unrealistic due to the large body of
conflicting evidence to date. However, the possibility of replacing tamoxifen with endoxifen therapy is
on the horizon, as the first phase I trial results have demonstrated acceptable toxicity with promising
efficacy in patients with endocrine-refractory, metastatic breast cancer [116].
3.5. Clinical Perspectives Based on Experience from a Personalized Tamoxifen Clinic
Clinical application of CYP2D6 genotyping as a way of predicting response to tamoxifen therapy
has not been widely accepted. Over the past seven years, as a part of our personalized medicine
research program, we have carried out CYP2D6 genotyping, and TDM measuring both tamoxifen and
endoxifen plasma concentrations using a LC-MS/MS system in approximately 800 patients. Shown
below are key observations from our clinic.
CYP2D6 genotyping alone is inadequate: We have observed that nearly 5% of patients, primarily
of Caucasian descent, are CYP2D6 PMs. However, only a portion (60%) of those predicted to be
PMs have endoxifen concentrations below 15 nM. Additionally, nearly 20% of patients predicted
to be CYP2D6 IMs were observed to have endoxifen concentrations of less than 15 nM. Current
clinical standard does not require or suggest tamoxifen dosing be changed based on CYP2D6 genotype.
However, we observed that a portion of patients are likely receiving sub-optimal benefit from tamoxifen
and patients with low endoxifen may benefit from higher daily tamoxifen doses.
Endoxifen measurement provides reassurance for patients regarding adequacy of tamoxifen
metabolism: In our clinic, we often hear from our patients that they experience little to no side effects
from tamoxifen, and are thus very concerned that they may not be attaining benefit from tamoxifen
therapy. Since our team not only carries out CYP2D6 genotyping, but also measures endoxifen plasma
concentration, we are able to demonstrate to our patients that in fact, presence or absence of side effects
cannot be used as a predictor of adequate tamoxifen metabolism.
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Tamoxifen and endoxifen measurement and patient compliance: Tamoxifen’s half-life is nearly
seven days, thus major changes in tamoxifen and endoxifen concentrations are reflective of the overall
tamoxifen compliance in the previous month prior to endoxifen measurement. Thus, when we observe
markedly lower than expected tamoxifen and endoxifen concentrations, we are able to discuss the
importance of medication compliance. Interestingly, our patients who are provided with their own
endoxifen metabolism data, demonstrate a greater willingness to continue tamoxifen. This holds true
even when patients experience significant side effects such as hot flashes, as they feel more reassured
regarding the adequacy of their tamoxifen metabolism, and the likelihood of long-term clinical benefit.
Endoxifen measurement is useful in quantifying the extent of tamoxifen drug interactions: One
of most common and clinically impactful roles of our tamoxifen clinic relates to our ability to quantify
tamoxifen drug interactions. A significant proportion of our tamoxifen patients are on antidepressants.
Low doses of antidepressants are often prescribed by oncologists to reduce hot flash symptoms.
Most antidepressants, particularly those in the SSRI class, act as inhibitors of CYP2D6 activity. SSRIs,
such as paroxetine, fluoxetine, and bupropion are well known potent inhibitors of CYP2D6. In fact, the
product monograph of such SSRIs cautions an interaction with tamoxifen that may lead to reduced
endoxifen formation. By measuring a patient’s endoxifen concentration, we can demonstrate the net
effect of such interactions. For patients with a low endoxifen concentration who are taking potent
CYP2D6 inhibitors, we are able to document a two-fold increase in endoxifen concentration when
such patients discontinue the SSRI or are switched to SSRIs with low to moderate CYP2D6 inhibitory
effect [60]. We note that patients who are CYP2D6 NMs or UMs tend to exhibit endoxifen concentration
above 15 nM, even when taking potent CYP2D6 inhibitors. Such information can be useful in some
cases where the patient is unwilling to switch to an alternative antidepressant. Conversely, we have
been able to document the deleterious effect of CYP metabolism inducing drugs, such as phenytoin
and rifampin, to a reduction in both tamoxifen and endoxifen plasma concentrations [98,117].
4. Conclusions
Genetic variation in CYP enzymes is increasingly recognized as clinically important. Although
the relationship between molecular basis of genetic variation in CYP enzymes and their expression
and function is well established, the application using such information to guide relevant drug therapy
in real-world patients has taken longer than expected. Much of the delay has been related to the
lack of randomized clinical trials data, as well as the cost-effectiveness of pharmacogenomics-based
approach. While current evidence may not support the implementation of pharmacogenomics testing
that may be impractical or unfeasible in certain clinical settings, the use of available genetic information
should be utilized to optimize drug therapy. Clinical guidelines have been established for warfarin
dosing in patients with known genetic information [118], and guidelines for tamoxifen are in currently
in development.
For warfarin, it is now becoming clear that preemptive genotyping can aid in better dosing
decisions, and the most recent large scale randomized trials data suggest genotype guided approach
results in better outcome. For medications such as tamoxifen, we are still awaiting decisive large scale
clinical outcomes data, in terms of optimal genotype or endoxifen-based dosing. Given that tamoxifen
is usually only a part of overall breast cancer treatment strategy (surgery, chemotherapy, radiation
therapy), it will likely require a very large sample size and a long follow-up period to provide such
conclusive evidence. What is becoming clear is that endoxifen is the major active metabolite, and the
observed endoxifen level could be viewed as a surrogate marker of adequate tamoxifen dosing, and
for mitigation of potentially deleterious drug interactions. The recently completed Phase I study using
endoxifen suggest that there is the potential for endoxifen therapy in the future, potentially bypassing
the current concerns relating to CYP2D6 and tamoxifen [116].
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